<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673463</url>
  </required_header>
  <id_info>
    <org_study_id>RG_14-150</org_study_id>
    <nct_id>NCT02673463</nct_id>
  </id_info>
  <brief_title>Spironolactone in Atrial Fibrillation</brief_title>
  <acronym>IMPRESS-AF</acronym>
  <official_title>Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess whether treatment with a drug called spironolactone, which is an&#xD;
      aldosterone inhibitor, can improve ability to cope with exertion, quality of life and ability&#xD;
      of the heart to relax better in symptomatic patients with atrial fibrillation with preserved&#xD;
      pumping capacity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMPRESS-AF study is a double-blinded randomised placebo-controlled trial of 2-year treatment&#xD;
      with an aldosterone antagonist, spironolactone (25mg once daily) vs placebo in 250 patients&#xD;
      with symptomatic chronic atrial fibrillation and preserved left ventricular contractility&#xD;
      (both added to the current optimised care). The trial will establish impact of spironolactone&#xD;
      on the primary outcome of exercise tolerance (peak oxygen consumption on cardiopulmonary&#xD;
      exercise testing) and secondary outcomes: (i) health-related quality of life (assessed using&#xD;
      the validated Minnesota Living with Heart Failure and EuroQol EQ-5D questionnaires&#xD;
      self-completed by patients), and (ii) left ventricular diastolic function (E/e' ratio on&#xD;
      echocardiography) - all assessed at baseline and at 2 years; (iii) rates of all-cause&#xD;
      hospitalisations during 2-year follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise tolerance (cardiopulmonary exercise testing)</measure>
    <time_frame>2 years of treatment</time_frame>
    <description>Improvement in exercise tolerance (assessed using peak oxygen consumption on cardiopulmonary exercise testing)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (MLWHF)</measure>
    <time_frame>2 years of treatment</time_frame>
    <description>Improvement in quality of life assessed using MLWHF questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ-5D)</measure>
    <time_frame>2 years of treatment</time_frame>
    <description>Improvement in quality of life assessed using EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular diastolic function</measure>
    <time_frame>2 years of treatment</time_frame>
    <description>Improvement in diastolic function assessed using echocardiography (E/e' ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance (6-minute walk test)</measure>
    <time_frame>2 years of treatment</time_frame>
    <description>Improvement in exercise tolerance (assessed using 6-minute walk test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of all-cause hospitalisations</measure>
    <time_frame>2 years of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous return to sinus rhythm on electrocardiogram</measure>
    <time_frame>2 years of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone 25 mg once daily for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo once daily for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25 mg once daily</description>
    <arm_group_label>Spironolactone</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Visually identical to spironolactone, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Permanent AF&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;= 55% as established by echocardiography&#xD;
&#xD;
          -  Able to perform cardio-pulmonary exercise testing using a cycling ergometer and&#xD;
             complete quality of life questionnaires in English or in their native language.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe systemic illness (life expectancy &lt;2 years)&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (e.g., requiring home oxygen or chronic&#xD;
             oral steroid therapy)&#xD;
&#xD;
          -  Severe mitral/aortal valve stenosis/regurgitation&#xD;
&#xD;
          -  Significant renal dysfunction (serum creatinine 220 Âµmol/L or above), anuria, active&#xD;
             renal insufficiency, rapidly progressing or severe impairment of renal function,&#xD;
             confirmed or suspected renal insufficiency in diabetic patients/ diabetic nephropathy&#xD;
&#xD;
          -  Increase in potassium level to &gt;5mmol/L&#xD;
&#xD;
          -  Recent coronary artery bypass graft surgery (within 3 months)&#xD;
&#xD;
          -  Use of aldosterone antagonist within 14 days before randomisation&#xD;
&#xD;
          -  Use of or potassium sparing diuretic within 14 days before randomisation&#xD;
&#xD;
          -  Systolic blood pressure &gt;160 mm Hg&#xD;
&#xD;
          -  Addison's disease&#xD;
&#xD;
          -  Hypersensitivity to spironolactone or any of the ingredients in the product&#xD;
&#xD;
          -  Any participant characteristic that may interfere with adherence to the trial protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory YH Lip, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduard Shantsila, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paulus Kirchhof, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Birmingham Institute of Cardiovascular Sciences</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B18 7QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

